Iloperidone — Membership Pricing

Other medications in Mental Health

• Imipramine
• Isocarboxazid
• Levomilnacipran
• Lisdexamfetamine
• Lithium
• Lithium Carbonate
• Lorazepam
• Loxapine

About Iloperidone

Iloperidone is a medication primarily prescribed to help manage the symptoms of schizophrenia. Understanding your treatment options and how to afford them is crucial. TheDrugClub is dedicated to helping members access their vital prescriptions, like iloperidone, often at significant savings. Learn more about this medication and how your membership can reduce costs on your path to better health.

What Iloperidone Treats

Iloperidone is an atypical antipsychotic medication primarily used to treat schizophrenia in adults. Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels, and behaves. Symptoms can include hallucinations (seeing or hearing things that aren't there), delusions (false beliefs), disorganized thinking, and a lack of motivation. Iloperidone helps to alleviate these symptoms, improving thought processes and emotional regulation, thereby enhancing a patient's overall quality of life. It is not a cure for schizophrenia but rather a tool to manage its challenging symptoms effectively.

How Iloperidone Works

Iloperidone exerts its therapeutic effects by acting on various receptors in the brain, particularly dopamine D2 and serotonin 5-HT2A receptors. By blocking these receptors, it helps to rebalance the chemical messengers in the brain that are thought to be disrupted in schizophrenia. This action helps to reduce positive symptoms like hallucinations and delusions,

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Iloperidone is approved for (FDA label)

FANAPT ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies (14.1) ]. Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies (14.2) ] . FANAPT is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults. ( 1 , 14.1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. ( 1 , 14.2 )

Source: Read the full FDA label on DailyMed. Label effective date: May 6, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Iloperidone (FDA label)

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. FANAPT is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. FANAPT is not approved for use in patients with dementia-related psychosis. ( 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: 33f60b40-3fca-11de-8f56-0002a5d5c51b. SPL document ID: 2609a5b3-d7ec-48a9-a32b-54a9b207f9aa. Label effective date: May 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Iloperidone (FDA label)

FANAPT tablets are available in the following strengths: 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. The tablets are white, round, flat, beveled-edged and identified with a logo “ ” debossed on one side and tablet strength “1”, “2”, “4”, “6”, “8”, “10”, or “12” debossed on the other side. 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg tablets. ( 3 ) Tablet Imprint

Source: FDA prescribing information (DailyMed). Set ID: 33f60b40-3fca-11de-8f56-0002a5d5c51b. SPL document ID: 2609a5b3-d7ec-48a9-a32b-54a9b207f9aa. Label effective date: May 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Iloperidone (FDA label)

The following adverse reactions are discussed in more detail in other sections of the labeling: Increased Mortality in Elderly Patients with Dementia-Related Psychosis [see Warnings and Precautions (5.1) ] Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis [see Warnings and Precautions (5.2) ] QT Prolongation [see Warnings and Precautions (5.3) ] Neuroleptic Malignant Syndrome (NMS) [see Warnings and Precautions (5.4) ] Tardive Dyskinesia [see Warnings and Precautions (5.5) ] Metabolic Changes [see Warnings and Precautions (5.6) ] Orthostatic Hypotension and Syncope [see Warnings and Precautions (5.7) ] Falls [see Warnings and Precautions (5.8) ] Seizures [see Warnings and Precautions (5.9) ] Leukopenia, Neutropenia and Agranulocytosis [see Warnings and Precautions (5.10) ] Hyperprolactinemia [see Warnings and Precautions (5.11) ] Body Temperature Regulation [see Warnings and Precautions (5.12) ] Dysphagia [see Warnings and Precautions (5.13) ] Priapism [see Warnings and Precautions (5.14) ] Potential for Cognitive and Motor Impairment [see Warnings and Precautions (5.15) ] Intraoperative Floppy Iris Syndrome [see Warnings and Precautions (5.16) ] Commonly observed adverse reactions (incidence ≥5% and 2-fold greater than placebo) were ( 6.1 ): Schizophrenia: dizziness, dry mouth, fatigue, nasal congestion, orthostatic hypotension, somnolence, tachycardia, and weight increased.

Source: FDA prescribing information (DailyMed). Set ID: 33f60b40-3fca-11de-8f56-0002a5d5c51b. SPL document ID: 2609a5b3-d7ec-48a9-a32b-54a9b207f9aa. Label effective date: May 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Iloperidone (FDA label)

FANAPT is contraindicated in individuals with a known hypersensitivity reaction to the product. Anaphylaxis, angioedema, and other hypersensitivity reactions have been reported [see Adverse Reactions (6.2) ] . Known hypersensitivity to FANAPT or to any components in the formulation. ( 4 , 6.2 )

Source: FDA prescribing information (DailyMed). Set ID: 33f60b40-3fca-11de-8f56-0002a5d5c51b. SPL document ID: 2609a5b3-d7ec-48a9-a32b-54a9b207f9aa. Label effective date: May 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Iloperidone (FDA label)

Cerebrovascular Adverse Reactions in Elderly Patients with Dementia- Related Psychosis: Increased incidence of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack). ( 5.2 ) QT prolongation: Prolongs QT interval and may be associated with arrhythmia and sudden death. Avoid use of FANAPT in combination with other drugs that are known to prolong QTc; use caution and consider dose modification when prescribing FANAPT with other drugs that inhibit FANAPT metabolism.

Source: FDA prescribing information (DailyMed). Set ID: 33f60b40-3fca-11de-8f56-0002a5d5c51b. SPL document ID: 2609a5b3-d7ec-48a9-a32b-54a9b207f9aa. Label effective date: May 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Iloperidone (FDA label)

The dose of FANAPT should be reduced in patients co-administered a strong CYP2D6 or CYP3A4 inhibitor. ( 2.2 , 7.1 ) 7.1 Clinically Important Drug Interactions with FANAPT Table 7 presents clinically important drug interactions with FANAPT. Table 7: Clinically Important Drug Interactions with FANAPT Strong CYP2D6 Inhibitors Clinical Impact Coadministration of fluoxetine with iloperidone increased exposure (area under curve, [AUC]) of iloperidone and its metabolite P88, by about 2- to 3- fold, and decreased the AUC of its metabolite P95 by one-half [see Clinical Pharmacology (12.3 , 12.5) ] . Coadministration of paroxetine with iloperidone resulted in increased mean steady-state peak concentrations of iloperidone and its metabolite P88, by about 1.6- fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half [see Clinical Pharmacology (12.3 , 12.5) ] . Intervention Reduce the dose of FANAPT by one-half when administered with strong CYP2D6 inhibitors.

Source: FDA prescribing information (DailyMed). Set ID: 33f60b40-3fca-11de-8f56-0002a5d5c51b. SPL document ID: 2609a5b3-d7ec-48a9-a32b-54a9b207f9aa. Label effective date: May 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.